Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed therapy (MDT) significantly prolongs poly-metastatic free survival (PMFS) and/or metastatic castration-refractory prostate cancer free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.

Trial Details

NCT ID
NCT05352178
Phase
PHASE3
Sponsor
Universitaire Ziekenhuizen KU Leuven
Status
RECRUITING
Cancer Type
Hormone-Sensitive Prostate Cancer
Interventions
  • Radiotherapy (SBRT) and/or surgery (metastasectomy)
  • Androgen deprivation therapy
  • Androgen receptor targeted therapy
Locations (sample)
  • Leuven, Belgium|50.87959,4.70093

Key Eligibility Criteria

  • Histologically proven initial diagnosis of prostate adenocarcinoma
  • Priory treated and controlled primary tumor
  • Biochemical recurrence defined by prostate-specific antigen (PSA) values \>0,2 ng/ml (i.e., two consecutive increases) following radical prostatect…
  • Oligorecurrent disease defined as a maximum of 5 extracranial metastases in any organ, diagnosed on PSMA PET-CT or PSMA PET-MRI reported according …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →